Morgan Stanley analyst Erin Wright lowered the firm’s price target on Envista (NVST) to $19 from $20 and keeps an Equal Weight rating on the shares. New medium-term guidance calls for more tempered topline growth and “notably lower implied margin targets,” the analyst tells investors. While stating that new management is “clearly taking a prudent approach,” the firm adds that the guidance does imply a dental market recovery.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVST:
- Envista Holdings: Hold Rating Amid High Valuation and Uncertain Market Conditions
- Envista Holdings’ Financial Volatility: Risks in Complex Accounting and Evolving Standards
- Envista Holdings: Hold Rating Amid Mixed Growth Signals and Market Challenges
- Envista Holdings’ Earnings Call: Cautious Optimism Amid Challenges
- Envista price target raised to $23 from $21 at Baird